Novadip and Cliniques universitaires Saint-Luc report positive results for compassionate use of NVD003 on four pediatric patients

NVD003 is a bone grafting…

Novadip receives RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia

Novadip is developing NVD003, an…

AstriVax Therapeutics Further Strengthens Team with the Appointment of Dieter Weinand as New Chair of the Board of Directors

US-based Dieter Weinand is the…

AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using LaunchiT technology

Third asset to advance into…

Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic

The program, licensed exclusively to…

Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb

No refractures were reported during…

Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogeneic product, in spine fusion

Novadip reports key nonclinical and…

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

Minoryx announces dosing of the…

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

Ona Therapeutics Strengthens Leadership Team…

Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field

At six months post-grafting surgery…